APVO Research and Charts

APVO - Aptevo Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2019-06-14 (Delayed quote data 2025-06-30)

Last 3.05	Change ⇓ -0.03 (-0.97%)	Volume 366,392
	Open 3.05	High 3.10	Low 2.90

8EMA (Daily) 3.41	40EMA (Daily) 3.08	50EMA (Daily) 2.95	STO (Daily) 3.903	MACD Hist (Daily) -0.458
8EMA (Weekly) 3.110	40EMA (Weekly) 38.41	50EMA (Weekly) 103.18	STO (Weekly) 48.009	MACD Hist (Weekly) 9.648


Company Profile
Aptevo Therapeutics Inc is a clinical-stage biotechnology company. It focuses on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. The company develops its drug candidates using its ADAPTIR platform. The products under its pipeline are APVO436, which targets CD123 and CD3 and redirects T-cell cytotoxicity to the tumor; ALG.APV-527, for the treatment of a broad spectrum of cancers over-expressing the 5T4 tumor antigen, including mesothelioma, non-small-cell-lung, head & neck, pancreatic, renal, ovarian, and bladder cancers; and APVO603.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.